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Abstract
Cell-mediated immunity was studied in 23 cases of advanced gastrointestinal cancer. The pa-
tients received levamisole at 150 mg/day for three consecutive days each week for four weeks. In
cases at the terminal stage of gastrointestinal cancer, the blastformation rate of peripheral blood
lymphocytes against phytohemagglutinin (PHA) after the administration of levamisole showed a
slight increase, but cases with blastformation rates over 40% increased markedly three or four
weeks after the initial administration of levamisole. The peripheral blood lymphocyte count
showed little change in these cases.
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Abstract. Cell-mediated immunity was studied in 23 cases of ad-
vanced gastrointestinal cancer. The patients received levamisole at
l50mgjday for three consecutive days each week for four weeks. In
cases at the terminal stage of gastrointestinal cancer, the blastforma-
tion rate of peripheral blood lymphocytes against phytohemagglutinin
(PHA) after the administration of levamisole showed a slight increase,
but cases with blastformation rates over 40% increased markedly three
or four weeks after the initial administration of levamisole. The pe-
ripheral blood lymphocyte count showed little change in these cases.
Recently, the progress and prognosis of carcinoma in cancer patients have
been investigated immunologically (1, 2). We have previously reported that cell-
mediated immunity in gastrointestinal cancer patients reflected cancer progress,
and that it was helpful in assessing the possibility of curative tumor resection and
the prognosis (3-5).
Mathe et at. (6) used bacille Calmette Guerin (BCG) and demonstrated the
efficiency of active immunotherapy of acute lymphoblastic leukemia in man for
the first time. Bast et at. (7) reported the effectiveness of BCG immunotherapy
for melanoma.
Various kinds of immunostimulants have been investigated for the purpose
of cancer immunotherapy.
In the present study, we used levamisole, a kind of immunostimulant, for
gastrointestinal cancer patients and found that levamisole was somewhat effec-
tive in activating cell-mediated immunity in cases of terminal stage of cancer
patients.
MATERIALS AND METHODS
The study comprised 23 cases of advanced gastrointestinal cancer (three
cases with curative resection, three of noncurative resection, and 17 of non-
resectable and recurrent cases) who received levamisole for its antitumor effect
and for the treatment of leukopenia following anticancer therapy.
Levamisole was administered orally in a dosage of l50mgjday for three
consecutive days a week for four weeks.
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As a parameter of cell-mediated immunity, the blastformation rate was
determined each week after levamisole administration. Peripheral lymphocyte
counts were also performed.
The blastformation rate of peripheral blood lymphocytes against PHA was
determined by the morphological procedure described previously (3-5).
RESULTS
In 23 cases given levamisole for four consecutive weeks, the blastformation
rate was 48.8± 17.0% in the third week compared with 39.2± 18.2% before
levamisoleadministration (p=O.I) and 47.4± 14.4% in the fourth week (0.1<
p<0.5). This indicated a slight rise in the latter half of the month after levami-
sole administration (Fig. 1). Cases with blastformation rates over 40% comprised
47.6% of the entire group before levamisole administration, and increased to
80% of the group by four weeks after levamisole administration (Table 1). The
peripheral blood lymphocyte count showed little variation throughout the course
of levamisole administration (Fig. 1).
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Fig. 1. Blastformation rate and lymphocyte count after administration of levami-
sole. Twenty-three cases received levamisole, p.o., 150 mg/day three consecutive days
in a week for four weeks. Data indicate mean ± S. D.
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TABLE 1. PERCENT OF CASES OVER 40% IN BLASTFORMATION RATE AFTER
ADMINISTRATION OF LEVAMISOLE 4 CONSECUTIVE WEEKS
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Weeks after levamisole
administration
o
1
2
3
4
Number of
cases
10/21*
19/22
8/20
11/16
12/15
Percent of
cases
47.6
63.6
40.0
68.8
80.0
* Number of cases over 40% in blastformation rate/number of cases examined.
A comparison of the results before levamisole administration with those
after levamisole administration showed that the blastformation rate rose slightly
in the first and the third weeks but dropped in the second and the fourth weeks
after levamisole administration (Table 2).
TABLE 2. PERCENT OF CASES SHOWING HIGHER VALUES AFTER LEVAMISOLE
ADMINISTRATION THAN VALUES BEFORE THE ADMINISTRATION
Weeks after levamiso1e administration
Examination
2 3 4
------- --------
Blastformation rate (12/20)* 60.0 ( 6/18) 33.3 ( 9/16) 56. 3 (7/15) 46.7%
Lymphocyte count (12/21) 57.1 (11/19) 57.9 (14/17) 82.4 (6/16) 37.5%
------
----_ ..._---
* Number of cases showing higher values after 1evamiso1e administration than values
before the administration/number of cases examined.
Peripheral blood lymphocyte counts after the start of levamisole administra-
tion in each individual rose until, and mostly during, the third week, but de-
creased in the fourth week (Table 2).
DISCUSSION
The interest around the world in nonspecific and specific immunotherapy as
an adjunct to cancer therapy has been focused on using BGG. Recently, levami-
sole has also been used for its activation of cell-mediated immunity and for its
antitumor effect.
Renoux and Renoux (8) showed that levamisole activates cell-mediated im-
munity in vivo. Since then, there have been several reports of the in vitro or in vivo
activation of cell-mediated immunity by, and the antitumor effect of, levamisole
(9-13).
Levamisole, chemically L-2, 3, 5, 6,-tetrahydro-6-phenyl-imidazo (2, I-b)
thiazole hydrochloride, is an isomer of tetramisole. Levamisole acts as a stimu-
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lant in those patients who have decreased cell-mediated immunity. This im-
munostimulation consists of four processes: 1. increase of the peripheral blood
lymphocyte count, 2. stimulation of T lymphocytes, 3. increase of reactivity to
dinitrochlorobenzene (DNCB) or purifed protein derivatives (PPD) 4. anti-tumor
effect resulting from the above I. to 3. processes. Contradictory reports have
appeared of the effect of levamisole on the peripheral lymphocyte count. Chan
et al. reported a definite increase in the peripheral lymphocyte count due to levam-
isole (14), while Levo et al. contended that it did not increase the lymphocyte
count but increased the percentage of active T lymphocytes (10). The effect of
levamisole on the stimulation of T lymphocytes was an increased blastformation
rate when lymphocytes were cultured with mitogen or antigen in vitro (II).
Various workers have shown that, when peripheral blood lymphocytes were
cultured with both levam:sole and PHA, Pockeed mitogen (PWM), or the lym-
phocytes of another person, the blastformat;on rate increased (11,12). However,
this only occurred with certain concentrations of levam;sole (11) and did not
occur without mitogen. In our results, the peak effect of levamisole (increased
blastformation rate against PHA) was in the third week after levamisole admin-
istration. The value, however, was only significant at the p = 0.1 level.
The administration of levamisole was associated with an increase in delayed
hypersensitivity in cancer patients. Levo et al. (15) reported that the admin:stra-
tion of levamisole to patients with Hodgkin's disease resulted in the convers'on of
their skin tests from negative to positive. Rojas et al. (16) also reported that
when the skin reactions to DNCB and PPD were compared in two groups of
before levamisole treatment and after 20 months of follow-up, levamisole treat-
ment was associated with an increase in positive DNCB tests, candida tests and
PPD tests compared with pretreatment in the same group. Similar results have
been reported by Tripodi et al. (13) and Verhaegen et al. (9).
In animal tumors, as well as in some human neoplasms, levamisole may
lead to antitumor effects (16, 17).
The administration of levamisole clinically is not uniform, but many au-
thors use the drug in a dose of 150 mg/day for three consecutive days a week,
continued every other week. There is as yet no report giving levamisole 150
mg/day for three consecutive days a week for four weeks.
There is no major toxicity attributable to levamisole. In our study, two
patients complained of urticaria and one patient complained of nausea. These
side effects disappeared soon after withdrawal of levamisole.
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